Market cap
$34.9m
End-of-day close multiplied by current shares on issue.
PHL · NZX
Promisia Healthcare is an NZX-listed healthcare / aged care company with FY22 - FY26 of published result briefings.
Snapshot
FY26, released 28 May 2026
| Metric | Value | Change |
|---|---|---|
| Revenue | $40.1m | ↑ +34.0% |
| EBITDAF | $6.6m | — |
| NPAT | $12.9m | ↑ +706.3% |
| Operating cash flow | $6.4m | ↓ -15.1% |
| OCF / EBITDAF % | 96.2%Outside range low ocf / ebitda cash conversion. 96.2%; 3-period range 107.1% to 197.5%. OCF / EBITDA cash conversion: 96.2%, below normal range; 3-period mean 167.2%, range 107.1%-197.5%. | — |
| Net debt | $38.5m | ↑ +32.5% |
| Net debt / EBITDAF | 5.82x | — |
| ROE % | 23.4% | ↑ +16.1pp |
| DPS | 0.0c | — |
| PBT | $13.9m | ↑ +286.1% |
Source: latest published briefing (FY26, released 28 May 2026). Change compares against the prior equivalent period: FY24, released 29 May 2024.
Valuation
A compact read on what the market price implies next to the latest filing data. The numbers are a starting point for comparison, not a recommendation.
The latest close and share count context for the market price.
Market cap
$34.9m
End-of-day close multiplied by current shares on issue.
How the market price compares with recent earnings and cash-flow inputs.
P/E
2.7x
Recent market cap compared with trailing earnings.
EPS
0.24
Recent filing-derived earnings per share.
PEG
0.03x
P/E compared with recent earnings growth.
EV/EBITDA
11.09x
Enterprise value compared with recent EBITDA.
P/FCF
Not available
Not meaningful when free cash flow is negative or unavailable.
P/B
0.63x
Market value compared with latest reported equity.
Yield and fund-style valuation where the company shape supports it.
Dividend yield
0.0%
Trailing dividends compared with the latest close.
Total return
Not available
Available once dividend and adjustment data are verified.
Daily closes use the full available width, with hover and touch readouts against real observations. Expand opens the chart at reading size.
Five years of daily closes, as at close, 5 June 2026. Weekends, suspensions, and listing gaps stay as natural gaps in the time scale.
Indexed lines compare direction from the first positive comparable filing point. The axis is an index, not dollars or cents.
Chat
Ask follow-up questions about Promisia Healthcare's latest result and company history.
Informational only. No buy, sell, hold, price-target, or personal financial advice.
Informational only. No buy, sell, hold, price-target, or personal financial advice.
Longitudinal view
The latest period is shown first.
| Metric | FY2612 MONTHS28 May 2026 | FY2412 MONTHS29 May 2024 | HY246 MONTHS28 November 2023 | FY2312 MONTHS30 May 2023 | FY2212 MONTHS30 June 2022 | Trend |
|---|---|---|---|---|---|---|
| Revenue | $40.1m | $29.9m | $12.9m | $23.8m | $19m | Chart |
| Revenue growth % | 29.1% | 25.6% | 10.7% | 25.5%Outside range low revenue growth. 25.5%; 3-period range 25.6% to 213.6%. Revenue growth: 25.5%, below normal range; 3-period mean 89.4%, range 25.6%-213.6%. | 213.6%Outside range high revenue growth. 213.6%; 3-period range 25.5% to 29.1%. Revenue growth: 213.6%, above normal range; 3-period mean 26.7%, range 25.5%-29.1%. | Chart
|
| EBITDAF | $6.6m | — | $1.6m | $3.6m | $4.5m | Chart |
| EBITDAF margin % | 16.5% | — | 12.4% | 15.0% | 23.5%Outside range high ebitda margin. 23.5%; 3-period range 12.7% to 16.5%. EBITDA margin: 23.5%, above normal range; 3-period mean 14.7%, range 12.7%-16.5%. | Chart
|
| PBT | $13.9m | $3.6m | -$0.1m | $0.5m | $1.9m | Chart |
| PBT growth % | 107.5% | 620.0% | — | -73.7% | — | Chart |
| NPAT | $12.9m | $1.6m | -$0.2m | $0.7m | $2m | Chart |
| NPAT growth % | 89.7% | 128.6% | — | -65.0% | n/m | Chart |
| Operating cash flow | $6.4m | $7.5m | $2.1m | $7.1m | $4.8m | Chart |
| OCF / EBITDAF % | 96.2%Outside range low ocf / ebitda cash conversion. 96.2%; 3-period range 107.1% to 197.5%. OCF / EBITDA cash conversion: 96.2%, below normal range; 3-period mean 167.2%, range 107.1%-197.5%. | — | 129.6% | 197.5%Outside range high ocf / ebitda cash conversion. 197.5%; 3-period range 96.2% to 197.1%. OCF / EBITDA cash conversion: 197.5%, above normal range; 3-period mean 133.5%, range 96.2%-197.1%. | 107.1% | Chart
|
| FCF pre-lease | -$0.17m | $7.2m | $1.9m | -$6.8m | $4.3m | Chart |
| FCF post-lease | -$0.17m | — | — | — | $4.3m | Chart |
| DPS | 0.0c | — | — | — | — | — |
| ROE % | 23.4% | 7.3% | -0.8% | 3.4% | 10.9% | Chart |
| Net debt | $38.5m | $29m | $30.1m | $28.8m | $14.7m | Chart |
| Net debt / EBITDAF | 5.82x | — | 18.79x | 8.04xOutside range high net debt / ebitda. 8x; 3-period range 3.3x to 7.64x. Net debt / EBITDA: 8.00x, above normal range; 3-period mean 5.59x, range 3.30x-7.64x. | 3.3xOutside range low net debt / ebitda. 3.3x; 3-period range 5.82x to 8x. Net debt / EBITDA: 3.30x, below normal range; 3-period mean 7.15x, range 5.82x-8.00x. | Chart
|
| Debtor days | — | — | 32 | 22 | 20 | Chart |
| Total assets | $199.5m | $84.3m | $73.6m | $71.8m | $51.5m | Chart |
Reference: annolyse.ai/companies/phl
Note: Figures are shown as reported. Half-year and full-year absolute values are not directly comparable. Growth rates and ratios are the meaningful comparison across mixed periods.
These charts use verified published filing periods only. Gaps are not interpolated, and mixed half-year/full-year histories are split into separate series.
Reported revenue across covered periods.
Like-period revenue growth where comparable.
Company-specific earnings measure where disclosed.
EBITDA-equivalent margin where revenue and earnings are source-backed.
Statutory profit after tax.
Cash generated from operations.
Additional verified filing metrics for this company. Each point links back to a published briefing period in the source data contract.
Cash conversion against earnings.
Operating cash flow less capex before leases.
Free cash flow after lease payments where available.
Return on equity.
Borrowings less cash; negative values indicate net cash.
Leverage ratio, suppressed where earnings are not meaningful.
Dividend per share declared for the period.
Receivables days where the working-capital inputs are source-backed.
Per-period working-capital absorption or release, from the same published history. Positive values are working-capital build; negative values are release.
The setup & the reality
The latest result is checked against what the prior briefing said to watch.
Historical setup
From PBT surged on a 25.6% revenue lift driven by prior-year acquisition
No formal earnings targets were disclosed for FY24, so there is no stated benchmark against which to judge the result. Management's commentary emphasises second-half momentum, and the half-year shape supports this: first-half NPAT was a NZ$0.2m loss, meaning the NZ$1.8m implied second-half NPAT carried essentially all of the annual profit. The 10% operating revenue growth and declining underlying EBITDAF suggest the business is still embedding the acquisition and working through cost-base management, rather than demonstrating operational leverage.
The stated strategy centres on occupancy improvement, revenue diversification, and network growth — but no FY25 targets are given. Whether the second-half momentum can be sustained, and whether the underlying EBITDAF can return toward its prior-year level, are the key unresolved forward questions this release does not answer.
Open questions
This briefing cannot assess the recoverability of the deferred tax asset, the sustainability of second-half occupancy rates, or the terms of the debt facilities that underpin the company's financial flexibility.
Archive
Every published Annolyse briefing for this company appears here in reverse chronological order.
FY26 · Released 28 May 2026
Full-year Cromwell consolidation and a sharp H2 earnings swing lift reported NPAT while net debt/EBITDAF falls from 11.1x to 5.8x.
FY24 · Released 29 May 2024
Revenue growth of 25.6% flatters the comparison because FY23 included a major acquisition, while a negative effective tax rate of -54.6% inflates
HY24 · Released 28 November 2023
Promisia's aged-care operations grew the top line solidly, but earnings turned negative as cost growth absorbed the revenue gain, leaving a NPAT loss
FY23 · Released 30 May 2023
A 25.5% revenue uplift was more than consumed by higher operating costs, lifting net debt to EBITDA to 8.0x and compressing PBT to NZ$0.5m.
FY22 · Released 30 June 2022
Headline +213.6% growth reflects the December 2020 acquisition lapping into a full period, not underlying expansion of the existing footprint.
Get the next Promisia Healthcare result briefing and five-year history updates by email.